Compare MOLN & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MOLN | BCIC |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 159.5M |
| IPO Year | 2021 | N/A |
| Metric | MOLN | BCIC |
|---|---|---|
| Price | $4.15 | $11.98 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.75 | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 77.7K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 15.90% |
| EPS Growth | N/A | ★ 330.32 |
| EPS | N/A | ★ 1.64 |
| Revenue | N/A | ★ $58,080,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $999.99 | $14.87 |
| P/E Ratio | ★ N/A | $7.29 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $11.12 |
| 52 Week High | $5.91 | $17.51 |
| Indicator | MOLN | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | N/A |
| Support Level | $4.21 | N/A |
| Resistance Level | $4.48 | N/A |
| Average True Range (ATR) | 0.17 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 27.08 | 0.00 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.